Bailard’s Oramed Pharmaceuticals ORMP Stock Holding History

Bailard’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$156K	Hold	32,478	–	–	﹤0.01%	746
2026 Q1	$110K	Buy	+32,478	New	+$110K	﹤0.01%	723

Other funds holding ORMP

Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return

Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $163M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bailard's ORMP Position: Q2 2026 in Review

Bailard held its Oramed Pharmaceuticals (ORMP) position steady in Q2 2026 at 32,478 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #746.

Bailard first reported a position in ORMP in Q1 2026 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

Bailard held 32,478 shares of Oramed Pharmaceuticals worth $156K as of Q2 2026.
Bailard left its Oramed Pharmaceuticals share count unchanged in Q2 2026.
Oramed Pharmaceuticals made up ﹤0.01% of Bailard's portfolio in Q2 2026, its #746 holding.
Bailard first reported a position in Oramed Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.